Drawing from Canada, Germany, and Thailand, this review argues that cannabis industry pressure and self-medication trends are driving medical marijuana expansion faster than the evidence for most claimed indications.
Policymakers, public health researchers, and anyone interested in how medical cannabis regulations develop.
No evidence of effectiveness for many self-medication indications
What the researchers found
Two pressures drive medical marijuana expansion: patients self-medicating for conditions without evidence of cannabis effectiveness, and cannabis industry lobbying for lenient regulations. Canada (early adopter), Germany (late adopter), and Thailand (middle-income) all illustrate this pattern. Lenient regulations that only require a prescription without specifying indications are likely to increase demand.
Why it matters
Medical marijuana programs are often seen as harm reduction, but if regulations are too lenient, they can become de facto recreational legalization without appropriate safety oversight.
The numbers in context
Three countries analyzed: Canada (early adopter), Germany (late adopter), Thailand (middle-income). Evidence lacking for many self-medication indications.
How the study worked
Policy analysis comparing medical marijuana programs in three countries: Canada, Germany, and Thailand.
What this study cannot tell us
Policy analysis with limited quantitative data. Focuses on three countries that may not represent all regulatory approaches. Industry influence is asserted but not quantified.
How to read the evidence
Moderate: thoughtful policy analysis drawing from multiple countries, but limited to qualitative assessment.
When this study was published
Published in 2019.
The bigger picture
The global shift toward medical cannabis legalization is driven by a mix of genuine patient needs, cultural trends, and industry interests. Policymakers need frameworks that balance access with evidence requirements.
Questions still open
- Should medical marijuana programs require evidence-based indications? How do you balance patient access with evidence requirements? Does industry pressure ultimately help or harm patients?
Common questions
Is medical marijuana just recreational in disguise?
Does this mean medical marijuana doesn't work?
Read the original research
Medical marijuana. What can we learn from the experiences in Canada, Germany and Thailand?
The International journal on drug policy, 74, 47-51
Citation
Rehm, Jürgen; Elton-Marshall, Tara; Sornpaisarn, Bundit; Manthey, Jakob. (2019). Medical marijuana. What can we learn from the experiences in Canada, Germany and Thailand?. The International journal on drug policy, 74, 47-51. https://doi.org/10.1016/j.drugpo.2019.09.001